7thAnnualWallStreetUnplugged

ManagementsGuidetoWallStreet&CapitalMarkets
July28,2011NewYork,NY

Sponsoredby

Agenda
8:309:30 9:3010:00 10:0010:15 10:1511:00 11:0011:30 11:3012:00 12:001:00 1:001:45 1:452:30 2:303:00 3:003:15 3:153:45 3:454:15 4:155:00 5:005:15 6:008:00 RegistrationandBreakfast ImplicationsofHealthcareReformonFDAProcesses AngelikiKotsianti,MD,PhD Director,GlobalR&D,Pfizer CarlosCordonCardo,MD,PhD ChairoftheDept.ofPathology,MountSinaiMedicalCenter RhondaGreenapple,MSPH PresidentandFounder,ReimbursementIntelligence Moderator:RosemaryMazanet,MD,PhD SeniorAdvisor,TheTroutGroup SocialMedia:NewTrendsinOnlineMarketing JustinSchreiberPresident&CEO,ExecutiveVideo ExploringInnovativeFinancing DaniellePetersFabiani&Company,Consultant GaryL.Disbrow,PhDBiomedicalAdvancedResearchandDevelopmentAuthority JohnPartigan,J.D.Partner,SecuritiesPracticeGroupLeader,NixonPeabody KarinHehenbergerSVP,StrategicAlliances,JuvenileDiabetesFoundation MichaelHermanSVP,Research&Investments,RoyaltyPharma Moderator:ChristopherD.Earl,PhD InvestorCommunication:PresentationContent&Style Presenter:JanSchultinkCEO,IdeaTransplant MinimizingDilutioninCapitalRaising DennisTurpin,CACFO,AEternaZentaris,Inc. FrederickW.DriscollCFO,Novavax,Inc. RichardD.Katz,MDCFO,Icagen,Inc. ShaliniSharpCFO,Agenus,Inc. Moderator:DeanColucci PresidentandGeneralCounsel,McNicoll,Lewis&Vlak NetworkingLunch BuySidePerspectives:Communication,Targeting&Analysis ChristianaBardon,MDChiefInvestmentOfficer,BurrageCapital DavidSable,MDPortfolioManager,SpecialSituationsFund FaraBerkowitz,PharmDManagingDirector,MeadowvalePartners,LLC. TomBrakel,MDSeniorPortfolioManager,FederatedInvestors,Inc. Moderator:ThomasFechtner VicePresident,TheTroutGroup SellSidePerspectives:AnalyzingOpportunitiesinaDynamicSector&Marketplace JasonButler,PhDResearchAnalyst,JMPSecurities JoshSchimmer,MDResearchAnalyst,LeerinkSwann SapnaSrivastava,PhDResearchAnalyst,GoldmanSachs Moderator:FranklinBerger,CFA ManagingDirector,FMBResearch FundingInnovation:AccessingRiskCapital GurRoshwalb,MDVicePresident,Venrock JayCecilManagingDirector,CaxtonAdvantage Moderator:MikeNowakManagingDirector,YorkvilleAdvisors CoffeeBreak TradingDynamics:TheMysteryBehindtheTrade JasonKelleyHealthcareTrader,Needham&Co. PatrickConnorsHealthcareTrader,GreenwichPrime Moderator:ToddJamesDirectorofCapitalMarketsAnalysis,TheTroutGroup FromINDtoAdCommswithYourScientificNarrative FrankCarilloPresidentandManagingDirector,ECG,Inc. BusinessDevelopmentforBiotech CasiDeYoungVP,BusinessDevelopment,ReataPharmaceuticals VipulaTailorDirector,WorldwideBusinessDevelopment,GlaxoSmithKline Moderator:AlanRoemer,MBA,MPH ManagingDirector,TheTroutGroup ClosingRemarks JonathanFassbergCEO,TheTroutGroup CocktailReception,ParkAvenuePenthouseLounge

ImplicationsofHealthcareReformonFDAProcesses

AngelikiKotsianti,Director,GlobalR&D Pfizer Dr.KotsiantireceivedherMD,PhDinMolecular PathologyattheAristotelianUniversityofThessaloniki, Greece.In1994,afteracademictenuresinGreeceand SwitzerlandshejoinedthePathologyDepartmentof MountSinaiMedicalCenter,NewYork,asafaculty memberandlatertheMolecularPathology DepartmentatMemorialSloanKettering,NewYork. In 2002, she moved to the Biotech world and became a strong pioneer developing first generation diagnostic and prognostic tests for different tumor types, based on Systems Pathologyapproach.Dr.KotsiantihasbeengrantednumerouspatentsintheUSAandEU forherworkinSystemsPathology. Late2006shemergedherscientific,clinicalandindustryexperienceandjoinedPfizerInc. intheGlobalClinicalTechnologyGroup,undertheHumanHealthTechnologiesGroupin New York, supporting the oncology portfolio. Shortly after, she was entrusted Global Medical position in the Oncology Group leading Global Clinical Trials for Pfizer Inc. for noveltargetedandimmunotherapeuticcompoundsforcancerpatients.Inthelast3years, shebecameGlobalOncologyLeadintheCenterofExcellenceintheEstablishedProduct Business Unit of Pfizer. Her responsibilities are to support, defend and manage multiple differentcomplexmedicalandproductissuesaroundtheglobe,regardingsafety,efficacy, risk: benefit indications, labeling, market authorizations and a plethora of initiatives involving over 100 Oncology products worldwide, including generic and bioequivalent submissions. CarlosCordonCardo, ChairofDepartmentofPathology MountSinaiMedicalCenter Carlos CordonCardo, MD, PhD, Chair of the Dept. of Pathology at the Mount Sinai Medical Center is a renowned physician scientist known widely for his research in experimental pathology and molecular oncology. A distinguished leader in the mechanismoftumorsuppression,Dr.CordonCardosresearchhasfocusedonanalysesof multidrug resistance and alterations of tumor suppressor genes in human cancer. He pioneered the development and implementation of an oncologic molecular pathology discipline, and recently he participated in the creation of the "systems pathology" platform,andiswidelyknownasanexpertonthedevelopmentofbiomarkersfortumor pathogenesisandpredictingclinicaloutcome.

ImplicationsofHealthcareReformonFDAProcesses

RhondaGreenapple,PresidentandFounder ReimbursementIntelligence Rhonda spent her career focused on assisting pharmaceutical, medical device, and biotechnology clientstogaingreateraccessandreimbursementfor their products. Her clients products ranged from unique chemical entities to highly competitive therapeuticcategories. Reimbursement Intelligences expertise and focus is dedicated to driving access and reimbursement initiatives from Phase II through the product lifecycle and serve to maximize commercial success. Rhondas clients include biotech companies looking at clinical trial design, reimbursement planning, licensing opportunity and pipeline asset evaluations,aswellasexitstrategies. Overthepast15years,shehasbeeninvolvedinthereimbursementlaunchplanningfor over 40 products. She has spoken both at professional meeting both domestic and internationallyonarangeoftopicsandhasbeenacolumnistinFiercePharmaIndustry Voicesonreimbursementissues. Rhonda received her B.S. from Cornell University and received her Master of Science in PublicHealthfromtheUniversityofNorthCarolina. RosemaryMazanet,SeniorAdvisor TheTroutGroup,LLC Dr. Mazanet trained in medicine and Heme/Onc at the BrighamandWomensHospitalandDanaFarberCancer Institute in the 1980s and started in the Biotech industry at Amgen, where she was head of Neupogen Clinical Development, and then Oncology Clinical Development. She has been a presenter in front of an FDAadvisorypanelonmorethanoneoccasion,andwas wellknowntotheinvestmentcommunitythatfollowed Amgen. In1998,shejoinedOraclePartners,LPwhereshewasawellrespectedbuysideanalyst. More recently, she has been a general partner of Apelles Investment Management, LP, has been Interim CEO for a number of transitioning companies, both public (Access Pharmaceuticals) and private (Diabetes America, Inc) as well as start up (Breakthrough Therapeutics,LLC).Shehasservedonnumerousboards,andiscurrentlyacoChairforthe University of Pennsylvania Making History Campaign ($3.5bn), where she has been a memberoftheExecutiveCommitteefortheHealthSystemsince2002.

Implications ofHealthcare Reformon FDA Processes

AngelikiKotsianti, M.D.,Ph.D. Director,GlobalR&D, Pfizer

RhondaGreenapple, MSPHPresident andFounder, Reimbursement Intelligence

Moderator: RosemaryMazanet, M.D.,Ph.D.Senior Advisor,TheTrout Group

ImplicationsofHealthcareReformonFDA Processes

SocialMedia:NewTrendsinOnlineMarketing

JustinSchreiber,PresidentandCEO ExecutiveVideo JustinSchreiberleadsExecutiveVideosstrategyand businessdevelopmentefforts.Heisastrongproponentof videocommunicationstrategyandassiststhefirmsclients withthedevelopmentanddistributionofcompellingvideo contentthatpositivelyinfluencesshareprice,liquidity,and revenue.Hehasproducedvideoswithmorethan300 companiesinthehealthcareandtechnologyspace. HewastheformerPresidentofOneMedForum,a conferenceforearlystageprivateandpubliclifescience companies.PriortothisMr.SchreiberservedasDirectorofBusinessDevelopmentfor TefenUSA,agloballifesciencesconsultancy.Hebeganhiscareerworkingasafinancial specialistforGainCapital,aleadingproviderofonlineforeignexchangetrading,asset management,andB2Bforexservices. HeholdsaBSinInternationalBusinessfromElizabethtownCollegeandaBAin InternationalManagementfromtheICNcoledemanagementinNancy,France.

SocialMedia:NewTrendsinOnlineMarketing

 Ms. Peters received her BA from McGill University in Montreal, Canada and her MA in CommercialDiplomacyfromtheMontereyInstituteofInternationalStudiesinMonterey, California. GaryDisbrow BiomedicalAdvancedResearchandDevelopmentAuthority Dr.GaryDisbrowjoinedBARDAinJanuaryof2007andbegan working on the smallpox vaccine program. Dr. Disbrow played a key role in awarding a contract for the modified vaccinia Ankara (MVA) vaccine and was instrumental in obtaining Secretarial approval for Advance Payment and Milestone payments awarded in the contract based on Project BioShield (PBS) and thePandemic and All Hazards PreparednessAct(PAHPA)legislation.Dr.Disbrowaccepted the position of Deputy Director CBRN Division of Countermeasures in October of 2008 andhasbeenoverseeingthebudgetforbothadvancedresearchanddevelopmentand PBSefforts. PriortojoiningBARDADr.DisbrowwasanAssistantProfessorofOncologyandPathology at Georgetown Medical Center where he worked on the development of the human papillomavirusvaccine(HPV)inadditiontotheviruslikeparticle(VLP)technology.Gary attendedtheUniversityofRochesterandGeorgetownUniversityforhisundergraduate andPh.D.respectively.

ExploringInnovativeFinancing

DaniellePeters,Consultant Fabiani&Company Since 2004, Ms. Peters has assisted Fabiani & Company clients in seeking federal funding and partnerships for research and commercialization of novel technologies. Ms.Petershasrepresentedcompaniesinthelifesciences, defense technology and green technology sectors. Ms. Petersmanagesclientrelationshipswithfederalagencies and Congress and has a proven track record in successfully positioning clients for federal funding and federalpartnershipopportunities.Onpolicymatters,Ms. Peters is engaged in issues that include patent reform, Small Business Administration Authorization, public health preparedness and incentives for clean energy commercialization.

JohnPartigan,Partner NixonPeabody John Partiganconcentrates his practice in federal securities law matters and mergers and acquisitions. His securities practice includes representing issuers in connection with primary and secondary public offeringsofdebtandequitysecurities,includinginitial public offerings, stock repurchase programs and privateplacementsofdebtandequitysecurities.Heis regularly involved in advising clients regarding disclosure requirements under the federal securities laws.Mr.PartiganisthechairmanofthefirmsnationalSecuritiesPracticeGroup.Heis a member of the NASDAQ Listings Qualifications Panel (2004present). Mr. Partigans mergers and acquisitions practice includes public and privately negotiated acquisitions and divestitures in a variety of industries, including digital media, broadcast and cable television,publishing,telecommunications,energyandsoftware. KarinHehenberger,SVP,StrategicAlliances JuvenileDiabetesFoundation Dr. Hehenberger holds M.D. and Ph.D. degrees from the KarolinskaInstituteinStockholm,Sweden,whereherthesis focused on diabetic complications. She continued her research as a JDRF postdoctoral fellow at the Joslin Diabetes Center at Harvard Medical School. She then movedintothebusinessaspectofmedicine,asastrategic management consultant at McKinsey & Co., where she focused on projects related to diabetes. Dr. Hehenberger also has experience in public and private equity, having been a partner in a European venturecapitalfirm,abuysidehealthcareequityanalyst,andontheseniormanagement teamofapublicbiotechcompany. Dr.HehenbergerisontheboardoftheRolfLuftFoundationforDiabetesResearchand theCoreSightCouncil.Inaddition,sheservesasafacultymemberatthedepartmentof ofMolecularMedicineoftheKarolinskaInstitute,asSeniorAdvisor,Biotechnologyand MedicalInnovations. MichaelHerman,SVP,Research&Investments RoyaltyPharma Mr.HermanjoinedRoyaltyPharmaatinception.From 1994 to 1996, Mr. Herman consulted for several financial concerns, including Apollo Advisors, Socit Gnerale and International Technology Investment Managers, the general partner of the proof of principlefunds.From1991to1994,Mr.Hermanwas an analyst in the fixed income division of Lehman Brothers.Mr.HermanreceivedaBAwithhonorsinPsychologyandEconomicsfromthe UniversityofMichigan.

ExploringInnovativeFinancing

ChristopherD.Earl ChristopherD.Earl,PhDisanentrepreneurandinvestor withtrackrecordoffosteringcompanygrowthbasedon innovativeproductsandunderservedmarkets,bothasa venturecapitalistandCEO.Hehasbroadexperienceasa CEOandboardmemberofsciencebased,notforprofit organizations,leadingresearch,policyandadvocacy efforts. Mostrecently,Dr.EarlwasthefirstPresidentandCEOofBIOVenturesforGlobalHealth (BVGH),anotforprofitorganizationharnessingbiotechnologyindustryR&Dtotreat infectiousdiseasesofthedevelopingworld.Previously,heservedasManagingDirector ofPerseusCapital,LP,andthePerseusSorosBioPharmaceuticalFund,L.P.Earlier,Dr. EarlwasPresidentandCEOofAvitechDiagnostics,Inc.,andaGeneralPartnerofPlant ResourcesVentureFunds. Dr. Earl serves on the Board of Directors of the Infectious Disease Research Institute, Asuragen, Inc., Mirna Therapeutics, Inc. and the Nature Conservancy of Maryland/DC, and advises Merck & Co.'s new Global Health Innovation internal venture investment group.HeisaTrusteeoftheCommitteeforEconomicDevelopment.Dr.Earlreceiveda BA in Biology from the University of Pennsylvania, and a PhD in Cellular and DevelopmentalBiologyfromHarvardUniversity.

ExploringInnovativeFinancing

ExploringInnovativeFinancing

 JanSchultink,CEO IdeaTransplant JanSchultinkisaninternationallyrecognized expertinpresentationdesign.Afteradecadeas astrategyconsultantwithMcKinsey&Company, JanisnowtheCEOofIdeaTransplant,designing professionalpresentationsforconferences,sales pitches,andinvestorrelations.Hisblog, blog.ideatransplant.comisoneoftheworld's mostreadresourcesonthesubjectof presentationdesign.

InvestorCommunication:PresentationContent&Style

Exploring Innovative Financing

InvestorCommunication: PresentationContent&Style

FrederickW.Driscoll,CFO Novavax,Inc. Frederick W. Driscoll joined Novavax in August 2009 as Chief Financial Officer after more than 30 years of financial management and operational experience in the biotechnology and medical device sectors. In 2007, he joined Genelabs, Inc., a publicly traded biotechnology company developing novel small molecules targeted at infectious diseases, where he served as Chief Financial Officer and became Chief Executive Officer prior to the companys acquisition by GlaxoSmithKline. From 2000 to 2006,Mr.DriscollwasemployedbyOXiGENE,Inc.,initially as Chief Financial Officer and subsequently as Chief Executive Officer. Mr. Driscoll has also served in senior financial positions at Collagenesis, Inc. and InstrumentationLaboratory. RichardKatz,CFO Icagen,Inc. Dr.Katzhasbeenourseniorvicepresident,financeand corporatedevelopment,andchieffinancialofficersince April2001.FromAugust1996to2001,Dr.Katzworked in the Investment Banking Division of Goldman Sachs, an investment banking firm, most recently as a vice president in the Healthcare Group. Prior to joining Goldman Sachs, Dr. Katz earned a Masters in Business AdministrationfromHarvardBusinessSchoolwherehe graduatedasaBakerScholar.Dr.KatzearnedhisM.D. from the Stanford University School of Medicine and completed an internship in general surgery at the Hospital of the University of Pennsylvania. Dr. Katz received his A.B. in applied mathematics with high distinctionfromHarvardUniversity.

MinimizingDilutioninCapitalRaising

DennisTurpin,SVPandCFO AEternaZentaris,Inc. Dennis Turpin joined the Company in August 1996 as Finance Director before being appointed Vice President andChiefFinancialOfficerinJune1999.Sincebeingwith ternaZentaris,M.Turpinhasbeenactivelyinvolvedin severalfinancingactivitiessuchaspublicofferingsandis very committed to investor relation activities on an internationallevel. Prior to joining terna Zentaris, Mr. Turpin was with Coopers&Lybrand(nowPricewaterhouseCoopers), CharteredAccountants,forovertenyears.

 ShaliniSharp,CFO Agenus,Inc. Shalini leads our finance and corporate development functions. Shalini joined Agenus in 2003 as Director of Strategic Planning. She was promoted to Senior Director, Strategic Planning and Corporate Development in 2005 and Vice President,ChiefFinancialOfficerin2006.Priorto joining Agenus, Shalini was Director of Strategic Planning at Elan Corporation, plc, where she served as chief of staff to the chairman of the board during the restructuringprocess andshedrovetocompletionanumberofstrategiccorporateandfinancialtransactions. ShaliniwaspreviouslyamanagementconsultantatMcKinsey&Company,specializing in pharmaceuticals and medical devices. She holds a BA and MBA from Harvard University.

DeanColucci,PresidentandGeneralCounsel McNicoll,Lewis&Vlak Mr.ColuccijoinedthefirmfromDLAPiperwherehewas a partner in the Corporate and Finance group for over 10 years. Prior to being a partner at DLA Piper, Mr. Colucci was at Cadwalader Wickersham & Taft. During his17yearlegalcareer,Mr.Coluccidevelopedabroad based corporate and finance practice that extended across capital markets, crossborder M&A, global infrastructure development and finance, and asset based finance. In the capital markets area, Mr. Colucci has been at the forefront of developingseveralAttheMarketOfferingproducts.Hehasbeenleadunderwriters counselinover50ATMtransactionsactingonbehalfof11differentinvestmentbanks. These deals raised more than $6 billion in equity capital for companies in the technology, life sciences, real estate investment trust, energy, transportation, and oil and gas sectors. Additionally, Mr. Colucci was intimately involved in structuring ATM products for both common and preferred stock as well as for dual listed issuers in CanadaandIsrael.Mr.ColuccihasanABfromCornellUniversity,anMAfromColumbia University,andaJDfromtheGeorgeMasonUniversitySchoolofLaw.Mr.Colucciholds hisSeries7,63,and24licenses.

MinimizingDilutioninCapitalRaising

MinimizingDilutioninCapitalRaising

ChristianaBardon,ChiefInvestmentOfficer BurrageCapital ChristianaBardonisaManagingDirectoratBurrageCapital,a hedge fund focused in biotechnology and healthcare. Previously, she was a health care analyst at Fidelity Investments. Chris earned her MS/BS from MIT, her MD from Harvard Medical School and her MBA from Harvard BusinessSchool.WhileatHarvardMedicalSchool,Christiana was the recipient of a Howard Hughes fellowship. She also completed a residency in internal medicine at the Brigham andWomensHospital. DavidSable,PortfolioManager SpecialSituationsFund David Sable MD, directs healthcare and life science investing for the Special SituationsFundsandisportfoliomanager of the Special Situations Life Sciences Fund.AftergraduatingfromtheWharton SchoolandtheUniversityofPennsylvania School of Medicine, residency in obstetricsandgynecologyatNewYorkHospitalCornellMedicalCenter,fellowshipat Brigham and Women's Hospital, and clinical practice at Harvard Medical School and MIT, he cofounded the Institute for Reproductive Medicine and Science at Saint BarnabasMedicalCenterinNewJersey. After leaving clinical medicine at age 43, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations group. Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches Entrepreneurship in Biotechnology at Columbias Graduate School of Arts and Sciences, has delivered keynote addresses to the American Fertility Society; and appearedontheCBSMorningNewsandABCWorldNewsTonight. FaraBerkowitz,ManagingDirector MeadowvalePartners,LLC Fara is a Managing Director & Head of Research at MeadowvalePartners.Shehas10yearsofhealthcareand6 years finance experience. Previously, Fara was a biotechnology & specialty pharmaceutical analyst at Sivik Healthcare and worked at Goldman Sachs in the Equity Re search Group, covering the specialty & generic pharmaceuticals sector where she launched the first ever generic sector coverage. Fara earned her MBA and CertificateinHealthcareManagementfromDukeUniversityandDoctorofPharmacy& B.S.fromRutgersCollegeofPharmacy.

Communication,Targeting&Analysis Communication,Targeting&Analysis

BuySidePerspectives: BuySidePerspectives:

ThomasFechtner,VicePresident TheTroutGroup Mr. Fechtner joined the firm in 2001 and has been involved in a wide variety of activities at Trout. His languageskills,knowledgeoftheEuropeanmarkets, and relationships have helped Trout clients expand their reach into Europe. Recently, Thomas was the keynote speaker at a CEOCFO event in Germany abouttheUSmarket,withanaudienceofmorethan 100 CEOs. His experience prior to joining the firm includesthesalesoffinancialproductsandbusiness communications.Hisroleininvestorrelationsforbothdomesticandinternationalclients includes many aspects, such as investor targeting and road show outreach/logistics, implementingstrategicplanning,developingconferencecallscriptsandinvestoraudits. He also plans and advises biotechnology related investor conferences and assists in developingeffectivewebsitesforclients. ThomascompletedhisstudiesattheUniversityofAugsburginGermany.Hehasearned thehonoraryTrouttitleofGlobalConcierge.HealsoholdsaSeries7securitieslicense.

Communication,Targeting&Analysis

BuySidePerspectives:

TomBrakel,SeniorPortfolioManager FederatedInvestors,Inc. Dr. Thomas M. Brakel is a senior portfolio manager and senior investment analyst at Federated Investors, Inc. Prior to joining the firm in 2003, he wasavicepresidentandsenioranalystcoveringthe biotechnologysectoratNewVernonAssociates,Inc. Previously, Dr. Brakel served as a portfolio manager at Biopharma Management Company from 2000 to March 2002. Prior to that, he was employed at BankInvest A/S. Before that, Dr. Brakel was a security analyst at Mehta Partners L.L.C. Earlier, he was the manager of new business development at Organon, Inc., a pharmaceuticalsubsidiaryofAkzoNobel.Previously,Dr.Brakelservedasananalystfor theBioPharmaFund.Hebeganhisinvestmentcareerin1998. Dr.BrakelobtainedanM.D.fromtheRotterdamMedicalSchoolatErasmusUniversityof RotterdamandM.B.A.fromtheGraduateSchoolofBusinessatStanfordUniversity.Heis fluentinDutchandGerman.

BuySidePerspectives: Communication,Targeting&Analysis

 Jason holds a PhD in neuroscience and a Bachelors degree in biology from Imperial CollegeLondon. JoshuaSchimmer,ManagingDirector LeerinkSwann Joshua Schimmer,M.D., is a Managing Director, Biotechnology analyst covering mid and largecap biotechnologycompaniesforLeerinkSwann. Priortojoiningthefirm,Dr.SchimmerwasaManaging Director for FTN Equity Capital Markets Corp, where he covered mid and largecap biotech companies.Before that,hespent two yearsas HealthcareEquitiesAnalystforbuysidefirm,Davidson Kempner Capital Management, LLC. Dr. Schimmer previously was aDirectorin BiotechnologyresearchatCowen&Companyforthreeyears,andbeganhiscareerin biotechnologyequityresearchatDeutscheBankSecurities. HeholdsaDoctorofMedicineDegreefromtheUniversityofTorontoandaMasterin BusinessAdministrationdegreefromHarvardUniversity.Dr.Schimmercompletedhis Internal Medicine residency at the University of Toronto, as well as a fellowship in Rheumatology,wherehewasChiefFellow.

SapnaSrivastava,ResearchAnalyst GoldmanSachs Sapna Srivastava is the senior large cap biotechnology analyst at Goldman Sachs since June 2010. Prior to that, she was an executive director andseniorsecurityanalystcoveringemergingtomid biotechnologyatMorganStanleyforoverfiveyears. She started her career as a security analyst at J.P.MorganSecuritiesin1999. Ms. Srivastava obtained a Ph.D. in Neuroscience in 1999 from New York University MedicalCenterandaB.S.fromtheUniversityofBombay,Indiain1994.

SellSidePerspectives:AnalyzingOpportunities inaDynamicSector&Marketplace

JasonButler,ResearchAnalyst JMPSecurities JasonButlerisaVicePresidentandresearchanalyst coveringthebiotechnologyindustry. Prior to joining JMP, Jason served as a senior associate equity analyst at Rodman & Renshaw covering biotechnology companies focused on therapies for metabolic and infectious diseases.

 FranklinBerger,ManagingDirector FMBResearch

Asaseniorportfoliomanageronthebuyside,Mr.BergerworkedatSectoralAsset Management as a founder of the smallcap focused NEMO Fund from 2007 through June2008. Mr.Bergerhasspent12yearsinsellsideequityresearch,mostrecentlyasManaging Director,U.S.EquityResearch,J.P.MorganSecurities,Inc.,fromMay1998toMarch 2003. During his five years at J. P. Morgan Securities, Inc., he was involved with the issuance of over $12 billion in biotechnology company equity or equitylinked securities. He was associated with several notable financings in the biotechnology sectorincludingtheGenentechIPO,thelargestbiotechnologyfinancingeverexecuted, thefirstlargeCelgeneCorporationfinancingsaswellasseverallargecapbiotechnology companies in their rapid growth phase. Mr. Berger began his career as a sellside analystatJosephthal&Co.in1991,subsequentlymovingtoSalomonSmithBarneyin 1997servingasDirector,EquityResearchandSeniorBiotechnologyAnalyst. TheWallStreetJournalselectedMr.BergerastheNo.1rankedbiotechnologyanalyst in its AllStar Analyst Survey in 1997 and No. 2 ranked in the WSJs 2000 Survey. In 2002,InstitutionalInvestorMagazinerankedhimonJ.P.Morgans3 rdplacedAllStar Research Team. In 2000, he became a Founding Fellow of the Biotechnology Study CenteratNewYorkUniversitySchoolofMedicine. Mr. Berger received his MBA degree from Harvard University in 1975; Johns Hopkins UniversityconferredbothhisMAandBAdegreesin1971and1972,respectively.

SellSidePerspectives:AnalyzingOpportunities inaDynamicSector&Marketplace

Mr. Berger started his consulting practice in 2003 after leaving J. P. Morgan Securities, Inc. as their head of biotechnology research. His clients are exclusively biotechnology industry participants including major biopharmaceutical firms, midcapitalization biotechnology companies, specialist asset managers and venture capital companies. Assignments include business development, strategic advisory/financings, partnering and clinical trial strategy.

SellSidePerspectives:AnalyzingOpportunities inaDynamicSector&Marketplace

GurRoshwalb,VicePresident Venrock Gur joined Venrock in 2008. Prior to joining Venrock, he was a vice president and senior researchanalystatPiperJaffray&Co.,focusingon specialty pharmaceuticals and small cap biotech companies. In this role, Gur was responsible for analyzing;valuingandpublishingresearchonboth publiclytradedandprivatelyheldbiotechandspecialtypharmaceuticalcompanies.Gur wastrainedininternalmedicineattheMountSinaiMedicalCenter,NewYork,where he also served as chief resident, and subsequently spent several years in private practiceasaninternistinNewYork. JayCecil,ManagingDirector CaxtonAdvantage Jay Cecil joined Caxton Advantage in 2006. Jay has 14 years of experience in the life sciences industry. Prior to joining the Fund, he was a Vice President in the Life Sciences Investment Banking Group at Piper Jaffray. Before Piper Jaffray, Jay worked within the Health Care Investment Banking Group at Montgomery Securities. During his years in life sciences banking, Jay completed over 60 financingandacquisitiontransactionsworthover$5.6billionforarangeoflifescience clients including Anesta, MGI Pharma, Biomarin Pharmaceuticals, Alexion Pharmaceuticals and ILEX Oncology. Since joining the fund, Jay has played an active role in a number of new investments, including VIVUS, Corthera, Regado Biosciences andAntheraPharmaceuticals. JayearnedanMBAfromTheWhartonSchool,UniversityofPennsylvaniaandanMSin Biotechnology from the University of Pennsylvania with a concentration in Immunology. He graduated Phi Beta Kappa from Lehigh University with a degree in Economics.

FundingInnovation:AccessingRiskCapital

 FundingInnovation:AccessingRiskCapital

MikeNowak,ManagingDirector YorkvilleAdvisors MikeleadsYorkville'sHealthcareInvestmentTeamwith over twenty years' experience structuring innovative financing products for private equity and midstage firms.PriortojoiningYorkvilleAdvisors,Michaelwasa GeneralPartneratTVMCapital,abilliondollarEuroUS venture fund. He also has entrepreneurial, business developmentandinvestmentexperiencefromworkasa cofounderoftheXeroxVentureLabatXeroxPARC,asa VP Business Development for an emerging high tech consulting practice at McKinsey & Co., and as a Manager of two $100M investment programsattheAdvancedTechnologyProgramatNIST,USDepartmentofCommerce. Michael earned an MBA from the Wharton School at the University of Pennsylvania andaPhDinPhysicsfromtheUniversityofCalifornia,SantaBarbara.Heworkedasa postdoctoral scientist at Bell Labs (Bellcore), Princeton University, and at the CEA researchlabsinSaclay,France.HereceivedhisBAinPhysicsfromCornellUniversityin Ithaca,NY.

FundingInnovation:AccessingRiskCapital

 JasonKelley,ManagingDirector,Institutional Sales&Trading,HealthcareTrader NeedhamandCompany Jasonhasover15yearsofsalesandtradingexperience.Hecoverslargehedgefunds andinstitutionsforNeedhamandhasbeenatopproduceroverhistenure.Needham isaleaderinsmallcapgrowthresearch,investmentbankingandtrading. PatrickConnors,Founder,ManagingPartner GreenwichPrimeTradingGroup Mr. Connors has been a trader for almost two decades, with a special expertise in the health care,biomedical,andpharmaceuticalindustries. HebeganhiscareeratHerzog,Heine&Geduld in 1992 serving as a trading assistant. In 1994, he left to become an equity trader at Furman Selz Prime Trading Group. Subsequently, the firmwasacquiredbyINGBarings,whichinturnwasacquiredbyABNAmroinAprilof 2001. The team separated from ABN AMRO and began life as the independent GreenwichPrimeafewmonthslater.Mr.ConnorsearnedhisB.A.degreeinEconomics fromLehighUniversity. GreenwichPrimeTradingGroup,LLCisthepioneerofoutsourcedtradingservicesfor institutional clients. Greenwich's clients include large institutions, midsize funds, mutual funds, startups, funds of funds, private equity funds, family offices, endowments,andcompaniesconductingcorporatesharebuybacks.Greenwichoffers access to a wide universe of brokers, research, and trading information. The firm servesexclusivelyasanagentoftheclient,anditsbusinessconsistsonlyofourcore competencyoftrading. ToddJames,DirectorofCapitalMarketsAnalysis TheTroutGroup Mr.JamesmanagesTroutsCapitalMarketsAnalysis Desk.TheCMADeskprovidesbothcorporateclients and Wall Street with sector related market analysis and services. Todd has experience assisting Companies in their understanding of Wall Street, investortargeting,scenarioanalysis,andfinancings. Hehasdoneextensiveresearchintradingstrategies, technical analysis and activist investing within the biotechsector.HemanagesTroutsrelationshipwith its trading partner, Greenwich Prime Trading Group, to help provide liquidity to Trouts clients and fund managers. He joined the firm in 2006fromtheThomsonFinancialCapitalMarketsIntelligenceBiotechnologyTeam.

TradingDynamics:TheMysteryBehindtheTrade

Trading Dynamics:The Mystery Behindthe Trade

TradingDynamics: TheMysteryBehindtheTrade

FromINDtoAdCommswithYourScientificNarrative

FrankCarillo,PresidentandManagingDirector ECG,Inc. FrankCarilloisPresidentandManagingDirectorofECG,the communicationstrategycompany.UnderFranksguidance, ECGs healthcare practice consultants have achieved an impressive level of success. Since 1995, they have maintainedasuccessrateofnearly85%onpositivevotesin FDA Advisory Committees for product approvals. Frank himselfhassupportedhearingsandnegotiationsinover20 different therapeutic areas. In addition, he and his team have supported hearings and negotiations for nearly 100 differentteamspreparingforAdvisoryCommitteeMeetings. BeyondAdvisoryCommitteeMeetingproductapprovals,Frankscommunicationstrategy and coaching have helped teams prepare special issue hearings, negotiating study designs and risk management plans, and marshalling support for groundbreaking therapies and issues. Frank and ECG have a strong record of success in building the explanations and advocacy necessary for helping regulators and academicians see the benefitsinnewdatawhilemaintainingappropriatecontextaroundrisk. Inthedynamicandhighlychargedworldofhealthcaredeliveryandmanagement,Frank and his partners also consult and coach CEOs and senior executives of pharmaceutical companies, health care providers, experts from academia, legislators and consulting firmsonstrategiesthataddressthisvolatilenationalconcern. Frank and his partners are rhetoricians and therefore valued by the popular media as communications experts. Their opinions and analysis create a demand for appearances on radio, TV and inprint. Their commentsandbylines aboutargumentation andhigh stakescommunicationcontinuetoappearinhundredsofnewspapers,professionaland tradejournalsandpopularmagazines. TheyappeargloballyonCNN,ABC,NBC,CNBC,CBS,andFoxandareregularcontributors totheNewYorkMetromedia.Frankisalsosoughtafterasaspeakerforprofessional and medical societies and has presented at scores of meetings globally. He recently presentedonregulatorycommunicationatUCSanFranciscosAmericanCourseonDrug Development and Regulatory Sciences. He most recently was a guest speaker at invivodataPROficiency2011wherehediscussedtheemergingroleofPROinbothpre andpostapproval;hedidthisinthecontextofECGsrecentsuccesspreparingaclient foraMEDCACmeeting. FrankisagraduateoftheWhartonSchoolofBusinessattheUniversityofPennsylvania. He is also a member of The Princeton Club of New York and the Union League of Philadelphia and was visiting communications faculty at Loyola University New Orleans from1987to2005.

FromINDtoAdCommswithYour ScientificNarrative

 CasiDeYoung,VP,BusinessDevelopment ReataPharmaceuticals Ms. DeYoung is currently Vice President, Business Development at Reata Pharmaceuticals in Dallas, Texas. Previous roles have also included alliance management, portfolio management, commercial operations and management consulting in biotech pharmaceutical companies in the US and abroad. PriortoReata,sheservedasVicePresident,Business DevelopmentforODCTherapy.ShealsoheldU.S.and global positions at EMD Pharmaceuticals, the U.S. subsidiary of Germanybased Merck KGaA, now MerckSerono.Ms.DeYoungbeganhercareerinthe pharmaceuticals business with Accenture. She received a B.S. degree in ChemistryandMathematicsfromSouthwesternUniversityandanM.B.A.from theUniversityofTexas. VipulaTailor,Director, AllianceManagement,WorldwideBusiness GlaxoSmithKline Vipula has over 15 years of international business development, licensing, R&D, manufacturing, operations, management and commercialization experience within pharmaceuticals, medical devices/diagnostics, consumerproductsandHealthcarearenas. As a former Senior Healthcare Management Consultant, Vipula was responsible for strategic and structured deals for four of the top 10 pharmaceutical/healthcare companies. She was directly responsible for Business Development and Alliance management, M&A/strategic partnerships at country (KimberlyClark and Wyeth), regional(J&JEurope)andgloballevels(GSK).VipulaholdsanMBAfromUniversityof Phoenix, MS in Medical Immunology from the London University and Bachelors in Microbiology.SheisalsoaboardmemberofHealingHandsofJoy(HHOJ),anonprofit foundationhelpingwomenwithfistulatoreintegratebackinthesocietyandbecome healthambassadorsinEthiopia.

BusinessDevelopmentforBiotech

BusinessDevelopmentforBiotech

AlanS.Roemer,ManagingDirector TheTroutGroup Mr.Roemerhasover18yearsofexperienceinthe lifesciencesindustry.HejoinedtheTroutGroupin 2009from Zelos Therapeutics, wherehe served as Chief Financial Officer & Treasurer and was responsible for all finance, accounting, administration, legal, human resources, information technology and investor/media relationsfunctions. rwasatPharmasset(Nasdaq:VRUS)from19992008. PriortojoiningZelos,Mr.Roeme HewasPharmassetsfirstfulltimemanagementhire,thenresponsiblefordeveloping the early stage operational infrastructure, fundraising transactions, business developmentandinvestorrelations.Heraisedover$100millionofprivateandpublic (IPO) equity for Pharmasset. Prior to Pharmasset, Mr. Roemer was a healthcare consultant for BoozAllen & Hamilton and Deloitte Consulting, and he held various operationalrolesatBankofAmerica. Mr. Roemer received a Bachelor of Science in Business Administration from Georgetown University and M.B.A. and M.P.H. degrees from Emory University's GoizuetaBusinessSchoolandRollinsSchoolofPublicHealth.HealsoholdsSeries7,79 and63securitieslicenses.

BusinessDevelopmentforBiotech

JonathanFassberg,CEO TheTroutGroup Mr. Fassberg is the Founder and Chief Executive OfficerofTheTroutGroup. Hehasworkedinthelife sciences industry for nearly 20 years and been an advisor to senior management of over 100 companies,bothpublicandprivate.Priortofounding Trout in 1996, Jonathan was a sellside analyst at a healthcarefocused investment bank. Before his career on Wall Street, Jonathan spent four years at DuPont Pharma in various sales and marketing positions. JonathanholdsaBachelorofSciencedegreeinbiologyandchemistryfromTheUniversity ofNorthCarolinaChapelHillandaMasterofBusinessAdministrationdegreeinfinance fromNewYorkUniversitysSternSchoolofBusiness.HealsoholdsSeries7,24,79and63 securitieslicenses.

ClosingRemarks

TheTroutGroupcordially invitesyoutoour

7thAnnualWallStreetUnpluggedCocktailReception
Location:GansevoortParkAvenueHotel'sPenthouseLounge Time:6:008:00pm

OverlookingManhattan'sskyline,wewelcomeyoutojoinusforcocktails andhorsd'oeuvreswhilenetworkingwithlifescienceexecutives,fellow WallStreetcolleaguesandotherindustryprofessionals. Celebrating15yearsinbusiness,theTroutGroupisespeciallylooking forwardtothisevent,whichlastyearattractedover75companiesfrom thelifescienceandinvestmentcommunity.

GlobalTeam

GlobalClientRoster

Weprovideafullrangeofinvestorrelations&strategic advisoryservicestolifescience,cleantechnology& sustainabilitycompanies.

NOTES

NOTES

NOTES

NOTES

NOTES